Los Angeles, CA – September 4, 2025 – As industry scrutiny intensifies over cosmetic products making bold but unverified “exosome” claims, Biogenomics, a biotech company advancing regenerative aesthetics, has announced performance breakthroughs for its flagship innovation, Genovia. Unlike competitors who emphasize inflated particle counts, Genovia is engineered through a patented lactoferrin-enhanced process that delivers scientifically validated quality, safety, and functional performance.
“Exosomes aren’t about chasing numbers — they’re about results providers can trust and patients can see,” said a Biogenomics spokesperson. “That’s the standard Genovia delivers.”
Beyond the Numbers: Science That Performs
The aesthetics industry has been flooded with products boasting ten to hundreds of billions or even trillions of exosomes per vial—yet clinics often report inconsistent results.
Context matters: In standard stem cell cultures, exosomes represent only a tiny fraction of conditioned medium. Attempts to boost yield by over extending cultures through multiple passages (subculturing) can introduce phenotypic drift and reduced functional potency, undermining real-world performance.
Peer-reviewed research shows that lactoferrin can stimulate exosome secretion in human adipose-derived stem cells (hADSCs), yielding a ~362% increase per-cell output while preserving vitality. Building on this, Biogenomics has scaled the process into a GMP-compliant manufacturing system that consistently achieves up to 16× higher exosome yields per mL compared to conventional methods.
Why it matters: Providers no longer have to choose between yield and quality—Genovia delivers both, at scale.
“Our patented technology energizes stem cells to release exosomes of exceptional-quality that communicate more effectively with skin cells,” said Dr. Kim, scientific advisor to Biogenomics. “It’s precision biology designed for real-world aesthetics.”
Deeper Delivery, Cleaner Signal
Exosome performance depends on delivery, not just production. In independent 3D human skin-model studies, Genovia’s exosomes penetrated about five times deeper than conventional exosomes. The studies also reported a 238% stronger dermal uptake ‘green signal’ — a fluorescence-based measurement used to quantify exosome uptake — with lactoferrin-primed exosomes reaching the upper dermis within six hours. This deeper, faster penetration correlated with enhanced extracellular matrix activity, including improved collagen synthesis in fibroblasts.
Independent lab tests (MTT assays) further showed >30% stronger fibroblast proliferation — a proxy for greater cellular resilience and activity associated with healthier-looking skin.
To protect signal fidelity, Genovia undergoes 0.2-micron terminal filtration, to remove cellular debris and inflammatory proteins. The result is a cleaner biological signal, ensuring that what reaches the skin is precise, functional, and consistent.
Real-World Results for Providers and Patients
“I have been in the aesthetic and plastic surgery arena for 20 years. I have seen treatments and products come and go. My pursuit in my career has always been ‘how can we make patient recovery easier, simpler, and quicker,’ particularly with more aggressive laser procedures that yield the best results overall but endure the longest downtime. Using this particular formula topically post treatment has been a game changer for my patients in their recovery. I have had many patients express a noticeable difference with the increased speed of their overall recovery. I have used other Exosomes in the past with my patients, and they have been beneficial, but the Genovia Exosome Complex seems to be the best overall. I would highly recommend this product to enhance your patients’ overall experience and results,” noted Tricia Kelly, BSN, RN, Premier Plastic Surgery. “It has become a reliable complement to all our energy-based treatments.”
A Future Built on Transparency and Trust
With regulators and practitioners demanding greater accountability, Biogenomics is committed to setting a higher standard of transparency and trust. Genovia is manufactured under GMP standards in ISO 9001 certified facilities, with clear SOPs, batch records, and labeling that aligns with FDA guidance — so every lot is documented, traceable, and consistent.
Each lot is antibiotic-free at the final culture stage with single-donor sourcing and cleared through viral and mycoplasma panels. Biogenomics also requires adverse-event reporting and maintains third-party safety validation for transparency.
Its industry-leading 30-month shelf life in lyophilized format further demonstrates Biogenomics’ focus on long-term stability and practical usability for providers.
As more clinics integrate exosomes into their practice, Biogenomics remains focused on setting the highest standard for regenerative aesthetics.
“The industry doesn’t need bigger promises —it needs a legitimate foundation with real science that delivers consistent results providers can rely on and patients can see,” said the founder of Biogenomics. “At Biogenomics, our cornerstone is science and transparency,” the spokesperson added. “That’s how we intend to differentiate from marketing hype and help shape the future of regenerative aesthetics responsibly.”
About Biogenomics
Biogenomics is a biotech company dedicated to advancing regenerative aesthetics through science-backed innovation. Its flagship product, Genovia, is a patented topical exosome platform designed to redefine post-procedure recovery, skin vitality, and provider confidence through precision manufacturing and validated biological performance.
Learn more at www.thebiogenomics.com.
Media Contact
Biogenomics
Email: info@thebiogenomics.com
Website: www.thebiogenomics.com
References
- Kim J., You G.E., Woo M., Chang N.H., Lee J. Discovery of Lactoferrin as a Stimulant for hADSC-Derived EV Secretion and Proof of Enhancement of Resulting EVs through Skin Model. Int. J. Mol. Sci. 2021;22(20):10993. doi:10.3390/ijms222010993.